Metoprolol Succinate Extended Release & Ramipril Tablets – AMIPRIL 2.5/25

Metoprolol Succinate Extended Release & Ramipril Tablets – Stong Cardioprotection with Dual Action Control.

Amipril 2.5/25 – Ramipril 2.5mg + Metoprolol 25mg Extended Release Tab

In combination, Metoprolol Succinate Extended Release and ramipril Tablets offer a dual-mechanism approach to cardiovascular management. Ramipril, an ACE inhibitor, reduces vascular resistance and blood pressure by blocking the conversion of angiotensin I to angiotensin II. Metoprolol, a selective beta-1 blocker, decreases heart rate and myocardial oxygen demand. The combination is especially useful in hypertension, heart failure, and post-MI care.

Recommended by specialists:
✅Cardiologists – For managing hypertension, chronic heart failure, post-myocardial infarction, and ischemic heart disease.
✅General Physicians – For management of hypertension, particularly in patients requiring combination therapy

Key benefits of Metoprolol Succinate Extended Release & Ramipril Tablets – AMIPRIL 2.5/25:
✅Dual-mechanism action – RAAS Inhibition + Beta-Blockade as Ramipril inhibits the renin-angiotensin system, while Metoprolol reduces sympathetic drive, providing comprehensive blood pressure and cardiac workload control.
✅Superior Cardiovascular Risk Reduction—This treatment is Ideal for patients with hypertension and post-myocardial infarction because it improves cardiac output and prevents remodeling.
✅Once-daily dosing: Metoprolol in sustained–release form ensures stable plasma levels, enhancing patient compliance and maintaining 24-hour protection.

Indications:
✅Hypertension
✅Chronic Heart Failure
✅Ischemic Heart Disease
✅Post-Myocardial Infarction
✅Left Ventricular Dysfunction